Combined drug action of 2-phenylimidazo[2,1-b]benzothiazole derivatives on cancer cells according to their oncogenic molecular signatures.
The development of targeted molecular therapies has provided remarkable advances into the treatment of human cancers. However, in most tumors the selective pressure triggered by anticancer agents encourages cancer cells to acquire resistance mechanisms. The generation of new rationally designed targ...
Main Authors: | Alessandro Furlan, Benjamin Roux, Fabienne Lamballe, Filippo Conti, Nathalie Issaly, Fabrice Daian, Jean-François Guillemot, Sylvie Richelme, Magali Contensin, Joan Bosch, Daniele Passarella, Oreste Piccolo, Rosanna Dono, Flavio Maina |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3465283?pdf=render |
Similar Items
-
7-Nitro-2-phenylimidazo[2,1-b][1,3]benzothiazole
by: Alexander S. Bunev, et al.
Published: (2014-02-01) -
Hypermethylation of gene body CpG islands predicts high dosage of functional oncogenes in liver cancer
by: Maria Arechederra, et al.
Published: (2018-08-01) -
Tracking Dynamics of Spontaneous Tumors in Mice Using Photon-Counting Computed Tomography
by: Franca Cassol, et al.
Published: (2019-11-01) -
N-(2-Phenylimidazo[1,2-a]pyridin-3-yl)acetamide
by: Karla Fejfarová, et al.
Published: (2008-05-01) -
2-Isobutyl-6-phenylimidazo[2,1-b][1,3,4]thiadiazole
by: Hoong-Kun Fun, et al.
Published: (2011-02-01)